JP2013520971A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013520971A5 JP2013520971A5 JP2012555384A JP2012555384A JP2013520971A5 JP 2013520971 A5 JP2013520971 A5 JP 2013520971A5 JP 2012555384 A JP2012555384 A JP 2012555384A JP 2012555384 A JP2012555384 A JP 2012555384A JP 2013520971 A5 JP2013520971 A5 JP 2013520971A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- patient
- medicament according
- stem cells
- microvesicles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 230000001613 neoplastic effect Effects 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 230000037396 body weight Effects 0.000 claims 3
- 239000000824 cytostatic agent Substances 0.000 claims 3
- 231100000433 cytotoxic Toxicity 0.000 claims 3
- 230000001472 cytotoxic effect Effects 0.000 claims 3
- -1 Lapa Chinibu Chemical compound 0.000 claims 2
- 210000004504 adult stem cell Anatomy 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229960003957 dexamethasone Drugs 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229960004942 lenalidomide Drugs 0.000 claims 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 229960004528 vincristine Drugs 0.000 claims 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 239000005461 Canertinib Substances 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 206010061968 Gastric neoplasm Diseases 0.000 claims 1
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 claims 1
- 229950002826 canertinib Drugs 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims 1
- 229960001156 mitoxantrone Drugs 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960000688 pomalidomide Drugs 0.000 claims 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 1
- 229960001796 sunitinib Drugs 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 1
- 229960002066 vinorelbine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10425052A EP2363136A1 (en) | 2010-03-02 | 2010-03-02 | Microvesicles (MVs) derived from adult stem cells for use in the therapeutic treatment of a tumor disease |
| EP10425052.7 | 2010-03-02 | ||
| PCT/EP2011/052945 WO2011107437A1 (en) | 2010-03-02 | 2011-02-28 | Microvesicles (mvs) derived from adult stem cells for use in the therapeutic treatment of a tumor disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013520971A JP2013520971A (ja) | 2013-06-10 |
| JP2013520971A5 true JP2013520971A5 (cg-RX-API-DMAC7.html) | 2014-04-03 |
| JP5841952B2 JP5841952B2 (ja) | 2016-01-13 |
Family
ID=42306621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012555384A Active JP5841952B2 (ja) | 2010-03-02 | 2011-02-28 | 腫瘍性疾患の治療的処置にて用いるための成体幹細胞由来の微細小胞（ｍｖ） |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US9717760B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2363136A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5841952B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102781454B (cg-RX-API-DMAC7.html) |
| DK (1) | DK2542250T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2554492T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE026292T2 (cg-RX-API-DMAC7.html) |
| PL (1) | PL2542250T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2542250E (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011107437A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2363136A1 (en) * | 2010-03-02 | 2011-09-07 | Fresenius Medical Care Deutschland GmbH | Microvesicles (MVs) derived from adult stem cells for use in the therapeutic treatment of a tumor disease |
| CA2798900C (en) | 2010-05-12 | 2021-10-12 | Tengion, Inc. | Isolated secreted vesicles produced by bioactive renal cells |
| ITRM20110403A1 (it) * | 2011-07-28 | 2013-01-29 | Ospedale Pediatrico Bambino Gesu | Microvescicole isolate da cellule mesenchimali come agenti immunosoppressori. |
| CN102357071B (zh) * | 2011-10-26 | 2013-10-23 | 重庆医科大学附属儿童医院 | 载紫杉醇纳米微泡及其制备方法 |
| CN104136034B (zh) * | 2011-11-30 | 2018-04-24 | 安斯泰来再生医药协会 | 间充质基质细胞及其相关用途 |
| US8961956B2 (en) | 2011-11-30 | 2015-02-24 | Ocata Therapeutics, Inc. | Mesenchymal stromal cells and uses related thereto |
| US11286463B2 (en) | 2012-03-08 | 2022-03-29 | Advanced ReGen Medical Technologies, LLC | Reprogramming of aged adult stem cells |
| CN104471059B (zh) | 2012-07-12 | 2018-04-17 | 珠海横琴爱姆斯坦生物科技有限公司 | 人胚胎干细胞衍生的间充质样干细胞、方法及其应用 |
| US10772911B2 (en) | 2013-12-20 | 2020-09-15 | Advanced ReGen Medical Technologies, LLC | Cell free compositions for cellular restoration and methods of making and using same |
| US20150174166A1 (en) | 2013-12-20 | 2015-06-25 | Advanced ReGen Medical Technologies, LLC | Compositions for Cellular Restoration and Methods of Making and Using Same |
| EP4445915A3 (en) * | 2014-03-24 | 2025-01-22 | Advanced Regen Medical Technologies, LLC | Cell free compositions for cellular restoration and methods of making and using same |
| WO2015179301A1 (en) * | 2014-05-19 | 2015-11-26 | Eleftherios Papoutsakis | Megakaryocytic particles and microparticles for cell therapy & fate modification of stem and progenitor cells |
| WO2017190000A1 (en) | 2016-04-29 | 2017-11-02 | Advanced ReGen Medical Technologies, LLC | Microrna compositions and methods of making and using same |
| EP3724334A1 (en) * | 2017-12-14 | 2020-10-21 | Unicyte EV AG | Pharmaceutical carriers containing mirnas for use in the treatment of renal cancer |
| EP3740576A4 (en) | 2018-01-18 | 2021-10-20 | Advanced Regen Medical Technologies, LLC | THERAPEUTIC COMPOSITIONS AND THEIR PREPARATION AND USE METHODS |
| WO2019197442A1 (en) * | 2018-04-12 | 2019-10-17 | Unicyte Ev Ag | A combination of active ingredients for the treatment of tumor |
| CN111494417B (zh) * | 2020-02-10 | 2024-04-09 | 寇晓星 | 诱导性细胞外囊泡在制备治疗肿瘤药物中的应用 |
| CA3178268A1 (en) | 2020-05-11 | 2021-11-18 | Jonathan Thon | Compositions and methods related to megakaryocyte-derived extracellular vesicles |
| KR102601831B1 (ko) * | 2020-09-23 | 2023-11-14 | 대한민국 | 고형암 증식 억제 효과를 갖는 개과동물의 엑소좀 |
| EP4534649A1 (en) * | 2023-10-03 | 2025-04-09 | Unicyte AG | A method of qualifying as pharmaceutically active a batch of undifferentiated adult stem cells having the potential to differentiate along the hepatic lineage |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6088613A (en) * | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
| WO1998033486A1 (en) * | 1997-01-30 | 1998-08-06 | Quadrant Healthcare (Uk) Limited | Microparticles and their use in cancer treatment |
| ATE296113T1 (de) * | 1998-02-09 | 2005-06-15 | Bracco Research Sa | Zielgerichtete abgabe von biologische-aktive medien |
| US20020177551A1 (en) * | 2000-05-31 | 2002-11-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| US7128903B2 (en) * | 2001-10-03 | 2006-10-31 | Innovative Pharmaceutical Concepts (Ipc) Inc. | Pharmaceutical preparations useful for treating tumors and lesions of the skin and the mucous membranes and methods and kits using same |
| WO2005121369A2 (en) * | 2004-06-02 | 2005-12-22 | Sourcepharm, Inc. | Rna-containing microvesicles and methods therefor |
| US8148335B2 (en) * | 2004-06-23 | 2012-04-03 | Children's Hospital & Research Center Oakland | De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy |
| GB0501129D0 (en) * | 2005-01-19 | 2005-02-23 | Ribostem Ltd | Method of treatment by administration of RNA |
| WO2006126219A1 (en) | 2005-05-26 | 2006-11-30 | Fresenius Medical Care Deutschland G.M.B.H. | Liver progenitor cells |
| US20090000641A1 (en) | 2007-06-28 | 2009-01-01 | Applied Materials, Inc. | Methods and apparatus for cleaning deposition chamber parts using selective spray etch |
| ES2419129T3 (es) * | 2007-09-14 | 2013-08-19 | The Ohio State University Research Foundation | Expresión de miARN en microvesículas de sangre periférica humana y usos del mismo |
| WO2009050742A1 (en) | 2007-10-15 | 2009-04-23 | Fresenius Medial Care Deutschland Gmbh | Use of microvesicles (mvs) for preparing a medicament having adjuvant activity on endothelial cell transplantation, particularly in the treatment of diabetes by pancreatic islet transplantation, and related method |
| PL2211875T3 (pl) * | 2007-10-29 | 2013-11-29 | Fresenius Medical Care Deutschland Gmbh | Zastosowanie mikropęcherzyków (MV) pochodzących z komórek macierzystych do wytwarzania leku do regeneracji śródbłonkowej/nabłonkowej uszkodzonych lub poddanych urazowi tkanek lub narządów i związane z nimi sposoby in vitro i in vivo |
| NZ586497A (en) * | 2008-01-04 | 2012-07-27 | Lydac Neuroscience Ltd | Microvesicles |
| HUE026536T2 (en) * | 2008-02-22 | 2016-06-28 | Agency For Science Tech And Res (A Star) | Mesenchymal stem cell particles |
| EP2186883A1 (en) | 2008-11-04 | 2010-05-19 | Fresenius Medical Care | An isolated multipotent mesenchymal stem cell from human adult glomeruli (hGL-MSC), a method of preparing thereof and uses thereof in the regenerative medicine of the kidney |
| EP2363136A1 (en) * | 2010-03-02 | 2011-09-07 | Fresenius Medical Care Deutschland GmbH | Microvesicles (MVs) derived from adult stem cells for use in the therapeutic treatment of a tumor disease |
-
2010
- 2010-03-02 EP EP10425052A patent/EP2363136A1/en not_active Withdrawn
-
2011
- 2011-02-28 PL PL11705585T patent/PL2542250T3/pl unknown
- 2011-02-28 US US13/581,537 patent/US9717760B2/en active Active
- 2011-02-28 HU HUE11705585A patent/HUE026292T2/en unknown
- 2011-02-28 DK DK11705585.5T patent/DK2542250T3/en active
- 2011-02-28 ES ES11705585.5T patent/ES2554492T3/es active Active
- 2011-02-28 JP JP2012555384A patent/JP5841952B2/ja active Active
- 2011-02-28 EP EP11705585.5A patent/EP2542250B1/en active Active
- 2011-02-28 CN CN201180011925.0A patent/CN102781454B/zh active Active
- 2011-02-28 PT PT117055855T patent/PT2542250E/pt unknown
- 2011-02-28 WO PCT/EP2011/052945 patent/WO2011107437A1/en not_active Ceased
-
2017
- 2017-06-12 US US15/620,164 patent/US10105395B2/en active Active
-
2018
- 2018-09-10 US US16/126,364 patent/US20190060369A1/en not_active Abandoned
-
2023
- 2023-04-17 US US18/135,243 patent/US20230248774A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013520971A5 (cg-RX-API-DMAC7.html) | ||
| Dolivo et al. | Artemisinin and artemisinin derivatives as anti-fibrotic therapeutics | |
| ES2762250T3 (es) | Tratamiento combinado del cáncer | |
| JP2016528162A5 (cg-RX-API-DMAC7.html) | ||
| JP2015529234A5 (cg-RX-API-DMAC7.html) | ||
| RU2016144668A (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| JP2017506624A5 (cg-RX-API-DMAC7.html) | ||
| Welch et al. | Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study | |
| JP2011079858A5 (cg-RX-API-DMAC7.html) | ||
| JP2013155188A5 (cg-RX-API-DMAC7.html) | ||
| JP2015524444A5 (cg-RX-API-DMAC7.html) | ||
| JP2020509024A5 (cg-RX-API-DMAC7.html) | ||
| JP2012521435A5 (cg-RX-API-DMAC7.html) | ||
| CY1119805T1 (el) | Συστημα χορηγησης φαρμακων για τη χορηγηση πτωχως υδατοδιαλυτων φαρμακευτικως ενεργων ουσιων | |
| CN102065865B (zh) | 多发性骨髓瘤治疗 | |
| JP2013518124A5 (cg-RX-API-DMAC7.html) | ||
| RU2004111975A (ru) | Протопанаксадиол и протопанаксатриол и их применение в качестве синергических противораковых средств | |
| JP2020117553A5 (cg-RX-API-DMAC7.html) | ||
| WO2015032011A1 (zh) | 含有亚铁氨基酸螯合物的组合物在制备抗癌症的药物中的用途 | |
| JP2014506233A5 (cg-RX-API-DMAC7.html) | ||
| AR068901A1 (es) | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos | |
| JP2021509395A5 (cg-RX-API-DMAC7.html) | ||
| JP2019526559A5 (cg-RX-API-DMAC7.html) | ||
| JP2015507020A5 (cg-RX-API-DMAC7.html) | ||
| JP2008517991A5 (cg-RX-API-DMAC7.html) |